Pfizer Inc. (NYSE:PFE) Stake Cut by Aspiriant LLC

Aspiriant LLC reduced its holdings in Pfizer Inc. (NYSE:PFE) by 6.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 40,855 shares of the biopharmaceutical company’s stock after selling 2,621 shares during the period. Aspiriant LLC’s holdings in Pfizer were worth $1,134,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of PFE. GoalVest Advisory LLC raised its stake in shares of Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares in the last quarter. Creekmur Asset Management LLC purchased a new stake in shares of Pfizer during the 4th quarter worth about $32,000. VisionPoint Advisory Group LLC raised its stake in shares of Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares in the last quarter. Tennessee Valley Asset Management Partners purchased a new stake in shares of Pfizer during the 4th quarter worth about $36,000. Finally, DiNuzzo Private Wealth Inc. purchased a new stake in shares of Pfizer during the 4th quarter worth about $37,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Price Performance

Pfizer stock opened at $27.80 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. The company has a market capitalization of $157.53 billion, a PE ratio of -463.26, a price-to-earnings-growth ratio of 1.08 and a beta of 0.70. Pfizer Inc. has a one year low of $25.20 and a one year high of $37.80. The business has a 50 day simple moving average of $27.81 and a 200 day simple moving average of $27.69.

Pfizer (NYSE:PFE) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping the consensus estimate of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The business had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. During the same quarter last year, the company earned $1.23 EPS. Pfizer’s revenue was down 19.5% on a year-over-year basis. On average, sell-side analysts forecast that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be paid a $0.42 dividend. The ex-dividend date is Friday, July 26th. This represents a $1.68 annualized dividend and a dividend yield of 6.04%. Pfizer’s dividend payout ratio (DPR) is currently -2,799.53%.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. BMO Capital Markets reissued an “outperform” rating and set a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Wednesday. Finally, Morgan Stanley increased their price objective on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. Ten analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $35.86.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.